Literature DB >> 18056401

The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice.

Danielle G Souza1, Caio T Fagundes, Flavio A Amaral, Daniel Cisalpino, Lirlândia P Sousa, Angélica T Vieira, Vanessa Pinho, Jacques R Nicoli, Leda Q Vieira, Iolanda M Fierro, Mauro M Teixeira.   

Abstract

The appropriate development of an inflammatory response is central for the ability of a host to deal with any infectious insult. However, excessive, misplaced, or uncontrolled inflammation may lead to acute or chronic diseases. The microbiota plays an important role in the control of inflammatory responsiveness. In this study, we investigated the role of lipoxin A4 and annexin-1 for the IL-10-dependent inflammatory hyporesponsiveness observed in germfree mice. Administration of a 15-epi-lipoxin A4 analog or an annexin-1-derived peptide to conventional mice prevented tissue injury, TNF-alpha production, and lethality after intestinal ischemia/reperfusion. This was associated with enhanced IL-10 production. Lipoxin A4 and annexin-1 failed to prevent reperfusion injury in IL-10-deficient mice. In germfree mice, there was enhanced expression of both lipoxin A4 and annexin-1. Blockade of lipoxin A4 synthesis with a 5-lipoxygenase inhibitor or Abs against annexin-1 partially prevented IL-10 production and this was accompanied by partial reversion of inflammatory hyporesponsiveness in germfree mice. Administration of BOC-1, an antagonist of ALX receptors (at which both lipoxin A4 and annexin-1 act), or simultaneous administration of 5-lipoxygenase inhibitor and anti-annexin-1 Abs, was associated with tissue injury, TNF-alpha production, and lethality similar to that found in conventional mice. Thus, our data demonstrate that inflammatory responsiveness is tightly controlled by the presence of the microbiota and that the innate capacity of germfree mice to produce IL-10 is secondary to their endogenous greater ability to produce lipoxin A4 and annexin-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056401     DOI: 10.4049/jimmunol.179.12.8533

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?

Authors:  Sesquile Ramon; Steven F Baker; Julie M Sahler; Nina Kim; Eric A Feldsott; Charles N Serhan; Luis Martínez-Sobrido; David J Topham; Richard P Phipps
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

Review 2.  Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.

Authors:  Mauro Perretti; Jesmond Dalli
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

3.  Annexin A1 regulates intestinal mucosal injury, inflammation, and repair.

Authors:  Brian A Babbin; Mike G Laukoetter; Porfirio Nava; Stefan Koch; Winston Y Lee; Christopher T Capaldo; Eric Peatman; Eric A Severson; Roderick J Flower; Mauro Perretti; Charles A Parkos; Asma Nusrat
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.

Authors:  Vincenzo Brancaleone; Jesmond Dalli; Stefania Bena; Roderick J Flower; Giuseppe Cirino; Mauro Perretti
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

Review 5.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

6.  CFTR inhibition provokes an inflammatory response associated with an imbalance of the annexin A1 pathway.

Authors:  Jesmond Dalli; Guglielmo Rosignoli; Richard P G Hayhoe; Aleksander Edelman; Mauro Perretti
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

Review 7.  Resolvins and protectins in inflammation resolution.

Authors:  Charles N Serhan; Nicos A Petasis
Journal:  Chem Rev       Date:  2011-07-18       Impact factor: 60.622

8.  The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice.

Authors:  Danielle G Souza; Flavio A Amaral; Caio T Fagundes; Fernanda M Coelho; Rosa M E Arantes; Lirlandia P Sousa; Martin M Matzuk; Cecília Garlanda; Alberto Mantovani; Adriana A Dias; Mauro M Teixeira
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

10.  Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis.

Authors:  Matthew Spite; Lucy V Norling; Lisa Summers; Rong Yang; Dianne Cooper; Nicos A Petasis; Roderick J Flower; Mauro Perretti; Charles N Serhan
Journal:  Nature       Date:  2009-10-29       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.